Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Tuesday, November 10, 2020
PhoreMost and Oxford Biomedica have entered into a discovery collaboration to develop next-generation CAR-T cell therapies.
read more
Tuesday, November 17, 2020
PhoreMost and Oxford Biomedica have entered into a discovery collaboration to develop next-generation CAR-T cell therapies.
read more
Wednesday, January 08, 2020
PhoreMost has entered into a multi-project drug discovery collaboration with Boehringer Ingelheim.
read more
PhoreMost Ltd., has triggered a milestone payment in its multi-project target discovery collaboration with Boehringer Ingelheim. This was achieved by identifying and validating novel targets supporting Boehringer Ingelheim’s ambition to develop first...
read more
Wednesday, January 19, 2022
PhoreMost Ltd., has relocated its headquarters to Unity Campus, a high-specification technology and innovation park, owned by leading regional property developers and investors, Howard Group, in south Cambridge.
read more
Wednesday, January 22, 2020
PhoreMost has entered into a multi-project collaboration with Otsuka Pharmaceutical. Financial details of the agreement are not disclosed.
read more
Thursday, September 08, 2022
PhoreMost Ltd. has entered into a multi-project target discovery collaboration with Roche. Under the terms of the agreement, PhoreMost will receive an upfront payment and is eligible for preclinical success-based milestones. Further financial terms ...
read more
Phoenix Molecular Designs (PhoenixMD) has announced the completion of clinical trial supply manufacture for PMD-026.
read more
Phlow Corp. announced a significant expansion in its analytical capabilities, use of artificial intelligence (AI), workforce, and domestic infrastructure.
read more
Phlow Corp. and Antheia announced an ongoing partnership to onshore production of essential medicines and establish more efficient, agile, and resilient pharmaceutical supply chains in the United States.
read more
Phlexglobal, providers of Trial Master File (TMF) technology and services solutions, and LUZ, a language translation company for life sciences, have entered into a partnership to offer a full eTMF and document translation solution.
read more
Tuesday, February 16, 2016
Philogen S.p.A. has entered into a second collaboration with AbbVie to discover and develop novel types of armed antibody products.
read more
Philogen announced a collaboration and license agreement with Boehringer Ingelheim to discover and optimize novel small molecule-based therapeutics using Philochem’s ESAC Library Technology platform.
read more
Philogen S.p.A has entered into a Service and Supply Agreement with IBSA (Institut Biochimique SA) to produce a recombinant therapeutic protein at Philogen GMP Facilities in Siena (Italy).
read more
Philogen S.p.A has entered into a Service and Supply Agreement with IBSA (Institut Biochimique SA) to produce a recombinant therapeutic protein at Philogen GMP Facilities in Siena (Italy).
read more